This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the Efficacy and Safety of Otsuka's TSND-201 for the Treatment of PTSD
Ticker(s): OTSKYWho's the expert?
Institution: University of Minnesota
- Interventional Psychiatrist and Assistant Professor at the University of Minnesota Medical School.
- Manages 80 patients with treatment resistant depression and has personally treated 40-50 psychiatric DBS patients, including patients who have been in Abbott's prior BROADEN trial.
- Research interests include deep brain stimulation, vagus nerve stimulation and transcranial magnetic stimulation
Interview GoalThis call will discuss the current treatment landscape and the potential of TSND-201, a Neuroplastogen being developed by Otsuka for the treatment of PTSD including the publication in JAMA titled "Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD"
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
